Sign in
Taking people in United StatesNo phase

Studies gut bacteria and immunotherapy response in several solid cancers

Observes gut bacteria and immune response in adults treated with checkpoint inhibitors.

Key facts

Who runs it
VastBiome
Where
Elizabethtown, United StatesSee the site
Trial code
Registry title
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Status
Recruiting
People taking part
800 people, planned
Started
22 Nov 2021
Expected to end
14 Sept 2028
Type of study
Observational
Treatments tested
  • Checkpoint Inhibitor, Immune
Record updated
27 April 2022

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stage I-IV non-small cell lung cancer, melanoma, triple-negative breast cancer or kidney cancer who plan to start a checkpoint inhibitor, and who can give stool samples.

Age
18 years or older
Sex
Men and women
Disease stage
Stages I-IV primary non-small cell lung cancer, malignant melanoma, triple-negative breast cancer or renal cell carcinoma
Earlier treatment
Must plan to be treated at a partner cancer site with a checkpoint inhibitor (anti-PD-1, anti-PD-L1 or anti-CTLA-4), alone or with other treatment, as approved by the FDA label

Main reasons for not taking part

  • Mental incapacity
  • Incarcerated individuals
  • Pregnancy (by self-report)
  • Active brain metastasis
  • Checkpoint inhibitor given off-label or in a clinical trial, or active participation in an immuno-oncology trial or pharma-sponsored observational study

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Men or women ≥18 years of age
  • Screened negative for COVID-19 symptoms at time of consent, as per institutional policy and as applicable for the duration of the COVID-19 pandemic
  • Diagnosed with stages I-IV primary NSCLC, MM, TNBC or RCC
  • Plan to be treated at a partner cancer site with a checkpoint inhibitor (anti-PD-1, anti-PD-L1, or anti-CTLA-4) as a single agent or in combination with another checkpoint inhibitor or other treatment agent or modality (e.g., targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with FDA-labeled use of the agent
  • Able to provide informed consent and answer study questionnaires in either English or Spanish
  • Able to provide stool specimens for research purposes

Who cannot take part

  • Treatment with checkpoint inhibitor in off-label capacity or through a clinical/interventional trial
  • Mental incapacity
  • Incarcerated individuals
  • Pregnancy (by self-report of pregnancy status)
  • Experiencing active brain metastasis/metastases
  • Active participation in an immuno-oncology clinical/interventional trial or pharma-sponsored observational study

Where in United States

  • Baptist Health Clinical ResearchElizabethtown, United StatesContact: Diane Drobny, BSN, RN, OCN, CCRPTaking people

About the trial

What the trial wants to find out

The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. However, large prospective studies in humans with longitudinal sample collection and standardized methods are needed to understand how microbiota and their byproducts affect cancer therapies, particularly among patients undergoing identical therapy but experiencing different outcomes. The proposed observational study builds upon these hypotheses by proposing a large cohort design to further assess the associations between the gut microbiota (composition and function), host immune system, and ICI treatment efficacy across multiple cancer types.

Treatments tested

  • Checkpoint Inhibitor, Immune

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Plain-language title
Studies gut bacteria and immunotherapy response in several solid cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 April 2022